Home>Media>News
> Exelixis announces results from sub-group analyses of the phase 3 pivotal CELESTIAL trial of ...
Exelixis announces results from sub-group analyses of the phase 3 pivotal CELESTIAL trial of cabozantinib for advanced hepatocellular carcinoma presented at ASCO 2018
We use cookies to offer you a better experience on our site and analyze its audience. By continuing browsing, you accept the use OKMore information
YOU ARE ON THE SITE OF IPSEN GROUP
The corporate website of the Group is governed by the Code of Good Practices of the International Federation of Pharmaceutical Manufacturers Associations.
Certain information provided on the site may not be strictly applicable to your country of residence.
Usted está saliendo del sitio web ipsen.es. Este enlace le llevará a un sitio web en el que no se aplica nuestra Política de Privacidad. Usted es el único responsable de sus interacciones con ese sitio web.
You are now leaving the Ipsen Group website.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website, please click Continue. The information provided on this website may not necessarily be applicable to the Ipsen Group.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website (careers.ipsen.com), please click Continue.
You are now leaving the Ipsen Group website. If you would like to visit an affiliate website, please click Continue. The information provided on this website may not necessarily be applicable to the Ipsen Group.
